Streetbeat News

TVGN

Tevogen Bio Holdings Inc.

Industry

Biotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Open

1.12

Mkt cap

205M

Volume

202K

High

1.18

P/E Ratio

3.34

52-wk high

6.25

Low

1.12

Div yield

N/A

52-wk low

0.26

In Friday's after-market session, several healthcare stocks showed notable movements. Bluejay Diagnostics, China Pharma Holdings, and Imunon were among the top gainers, with increases of 11.0%, 10.15%, and 7.63% respectively. On the losing end, Compass Therapeutics, Akanda, and Portage Biotech saw significant declines. Accolade also rose by 5.83% following their Q4 earnings release.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 8:31 pm

Aon plc shares fell by 7.4% after reporting quarterly financial results below market expectations. Other stocks showed significant movement, with Biodexa Pharmaceuticals and Pineapple Energy among the top gainers, while iClick Interactive and Nuwellis were notable losers.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 5:56 pm

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced the elimination of $94.9M in liabilities through the conversion of promissory notes into common stock, now part of its 165 million outstanding shares. The company's CEO highlighted this financial improvement and introduced the Tevogen.ai initiative, aimed at leveraging AI in drug discovery, development, and distribution. Leadership appointments include Mittul Mehta as CIO and Head of Tevogen.ai, and Tapan V. Shah as Head of Investor Relations and Corporate Development. Tevogen Bio focuses on developing T cell therapeutics in virology, oncology, and neurology.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 1:30 pm

Alphabet Inc. reported first-quarter revenue of $80.539 billion, a 15% increase year-over-year, surpassing estimates. Earnings were $1.89 per share, beating forecasts. Alphabet announced a $70 billion share repurchase program and its first-ever quarterly dividend, causing shares to rise 11.9% in pre-market trading. Other stocks also moved significantly in pre-market trading, with notable gainers including Tevogen Bio Holdings, Pineapple Energy, and Freight Technologies, and losers such as Aclarion, Vincerx Pharma, and SCWorx Corp.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 12:18 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Tevogen Bio Holdings (TVGN) led the gainers with a 75.3% increase, while Processa Pharma (PCSA) experienced the largest drop among the losers, falling 15.6%. Other notable movers included Cryo-Cell International (CCEL) and Moleculin Biotech (MBRX) with substantial gains, and SCWorx (WORX) and Nuwellis (NUWE) with notable losses.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 12:06 pm

In Thursday's after-market session, health care stocks saw significant movements. Tevogen Bio Holdings led the gainers with a 51.8% increase, while Vincerx Pharma experienced the largest drop among the losers, declining by 17.5%. ResMed and DexCom reported their Q3 and Q1 earnings, respectively, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 8:32 pm

Super Micro Computer, Inc. (SMCI) shares fell by 13.2% after the company announced its third-quarter earnings date without providing preliminary estimates, unlike the previous quarter. Other stocks showed significant movement, with notable gainers including Next.e.GO N.V. (EGOX) and Redwoods Acquisition Corp. (RWOD), and losers like Sunshine Biopharma, Inc. (SBFM) and iSpecimen Inc. (ISPC).

Portfolio Pulse from Avi Kapoor

April 19, 2024 | 5:25 pm

Equifax Inc. reported lower-than-expected Q1 sales and adjusted its guidance below estimates, leading to a 9.5% drop in pre-market trading. Other stocks like Funko, Rani Therapeutics, Tevogen Bio, Synovus Financial, Bank of Hawaii, Etsy, and Snap-on also saw declines in pre-market trading due to various factors including weak sales and downgrades.

Portfolio Pulse from Avi Kapoor

April 18, 2024 | 1:03 pm

Live Nation Entertainment, Inc. (LYV) shares fell 7.8% in pre-market trading due to a report of an impending antitrust lawsuit by the Justice Department. Other stocks such as Inovio Pharmaceuticals (INO), Groupon (GRPN), Lyell Immunopharma (LYEL), ArcelorMittal (MT), Tevogen Bio Holdings (TVGN), Lennox International (LII), and Clean Energy Fuels Corp (CLNE) also saw declines in pre-market trading due to various reasons including underwritten offerings, tax authority actions, downgrades, and upcoming financial results.

Portfolio Pulse from Avi Kapoor

April 16, 2024 | 10:53 am

Applied Digital Corporation reported disappointing third-quarter financial results, leading to a sharp decline in its pre-market trading shares by 9.1%. The company's quarterly loss widened, and sales fell short of expectations. Other stocks also moved lower in Friday's pre-market session, including Tevogen Bio Holdings, Nurix Therapeutics (after pricing a public offering), XPeng Inc., Taysha Gene Therapies, Korea Electric Power Corporation (following a previous day's drop), Esperion Therapeutics, and JD.com.

Portfolio Pulse from Avi Kapoor

April 12, 2024 | 12:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.